Teva Pharmaceutical Industries Statistics
Share Statistics
Teva Pharmaceutical Industries has 1.15B
shares outstanding. The number of shares has increased by 1.17%
in one year.
Shares Outstanding | 1.15B |
Shares Change (YoY) | 1.17% |
Shares Change (QoQ) | 0.99% |
Owned by Institutions (%) | 58.69% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 1,224 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 28.43M, so 2.48% of the outstanding
shares have been sold short.
Short Interest | 28.43M |
Short % of Shares Out | 2.48% |
Short % of Float | 2.49% |
Short Ratio (days to cover) | 2.82 |
Valuation Ratios
The PE ratio is -15.21 and the forward
PE ratio is 6.01.
Teva Pharmaceutical Industries's PEG ratio is
-0.08.
PE Ratio | -15.21 |
Forward PE | 6.01 |
PS Ratio | 1.51 |
Forward PS | 1.2 |
PB Ratio | 4.63 |
P/FCF Ratio | 33.28 |
PEG Ratio | -0.08 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Teva Pharmaceutical Industries.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.98,
with a Debt / Equity ratio of 3.36.
Current Ratio | 0.98 |
Quick Ratio | 0.75 |
Debt / Equity | 3.36 |
Debt / EBITDA | 25.25 |
Debt / FCF | 24.14 |
Interest Coverage | -0.3 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $447,135.14 |
Profits Per Employee | $-44,297.3 |
Employee Count | 37,000 |
Asset Turnover | 0.42 |
Inventory Turnover | 2.82 |
Taxes
Income Tax | 676M |
Effective Tax Rate | -52.65% |
Stock Price Statistics
The stock price has increased by 1.13% in the
last 52 weeks. The beta is 0.63, so Teva Pharmaceutical Industries's
price volatility has been higher than the market average.
Beta | 0.63 |
52-Week Price Change | 1.13% |
50-Day Moving Average | 15.55 |
200-Day Moving Average | 17.53 |
Relative Strength Index (RSI) | 56.57 |
Average Volume (20 Days) | 12,431,270 |
Income Statement
In the last 12 months, Teva Pharmaceutical Industries had revenue of 16.54B
and earned -1.64B
in profits. Earnings per share was -1.45.
Revenue | 16.54B |
Gross Profit | 8.06B |
Operating Income | -303M |
Net Income | -1.64B |
EBITDA | 716M |
EBIT | -282M |
Earnings Per Share (EPS) | -1.45 |
Full Income Statement Balance Sheet
The company has 3.3B in cash and 18.08B in
debt, giving a net cash position of -14.78B.
Cash & Cash Equivalents | 3.3B |
Total Debt | 18.08B |
Net Cash | -14.78B |
Retained Earnings | -15.17B |
Total Assets | 38.41B |
Working Capital | 371M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 1.25B
and capital expenditures -498M, giving a free cash flow of 749M.
Operating Cash Flow | 1.25B |
Capital Expenditures | -498M |
Free Cash Flow | 749M |
FCF Per Share | 0.66 |
Full Cash Flow Statement Margins
Gross margin is 48.74%, with operating and profit margins of -1.83% and -9.91%.
Gross Margin | 48.74% |
Operating Margin | -1.83% |
Pretax Margin | -7.76% |
Profit Margin | -9.91% |
EBITDA Margin | 4.33% |
EBIT Margin | -1.83% |
FCF Margin | 4.53% |
Dividends & Yields
TEVA pays an annual dividend of $1.19,
which amounts to a dividend yield of 5.8%.
Dividend Per Share | $1.19 |
Dividend Yield | 5.8% |
Dividend Growth (YoY) | 0% |
Payout Ratio | -103.48% |
Earnings Yield | n/a |
FCF Yield | n/a |
Dividend Details Analyst Forecast
The average price target for TEVA is $24.5,
which is 44.5% higher than the current price. The consensus rating is "Buy".
Price Target | $24.5 |
Price Target Difference | 44.5% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Stock Forecasts Stock Splits
The last stock split was on Jul 1, 2004. It was a
forward
split with a ratio of 2:1.
Last Split Date | Jul 1, 2004 |
Split Type | forward |
Split Ratio | 2:1 |
Scores
Altman Z-Score | 0.31 |
Piotroski F-Score | 6 |